Biotech Values

[DewDiligence]

2Q08 Lovenox Sales by Region

Worldwide, Lovenox sales rose 5% year-over-year to an annualized rate of $4.0B; in the US, sales rose 7% year-over-year to $2.4B.

Sales in all regions fell in 2Q08 vs 1Q08 on account of contamination and supply issues with heparin and Lovenox itself. (In 1Q08, Lovenox sales were artificially high, stealing some sales from 2Q08, on account of the heparin recalls by Baxter and other suppliers. In 2Q08, there were supply problems in Europe for Lovenox itself due to contamination.)

Following are annualized sales in 2Q08
(dollar amounts based on current exchange rate):

US: €1.52B ($2.37B) (60% of total), +7% YoY, -11% QoQ
EU: €756M ($1.18B) (30% of total), -4% YoY, -11% QoQ
RoW: €264M ($412M) (10% of total), +10% YoY, -15% QoQ
===
Total: €2.55B ($3.97B), +5% YoY, -11% QoQ

http://en.sanofi-aventis.com/Images/080731_T2_Results_EN_tcm24-21170.pdf